Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer

NCT02810457 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

731

Enrollment

INDUSTRY

Sponsor class

Conditions

Carcinoma, Non-Small-Cell Lung

Interventions

DRUG: FKB238 (bevacizumab)
DRUG: Avastin (bevacizumab)
DRUG: Paclitaxel
DRUG: Carboplatin

Sponsor

Centus Biotherapeutics Limited